ALXO
Alx Oncology
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 1.66B; Volume: 83.08K; AvgVol 3m: 178.80K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.74; EPS growth quarter/prev quarter: ;
EPS growth this year: -33.70%; EPS growth past 5 years: ;
EPS ttm: -3.47;
P/S: 356.23; P/B: ; P/Cashflow: 13.44; P/FCF: ;
Sales: 7.28M; Sales growth quarter/prev quarter: -50.00%; Sales growth past 5 years: ;
Profitability:
Gross Margin: 9.10%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: ; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 2.60%; Insider Transactions:0.00%;
Institutional Ownership: ; Institutional Transactions: ;
Data update: 07.10.2020.